A Phase 4, Open-label Study to Evaluate Persistence of the Antibody Response Elicited by Prevenar in Healthy Children in China Who Have Been Previously Immunized With a 4-dose Series of a Pneumococcal Conjugate Vaccine During Infancy in Study 0887x-101518
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Pneumococcal 7-valent CRM197 vaccine conjugate (Primary) ; DTaP vaccine
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Pfizer
- 28 Oct 2016 New trial record
- 08 Sep 2016 Results assessing long-term antibody persistence (3 years after last dose), published in the Vaccine Journal.